KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Mark Iwicki, Chair and Chief Executive Officer of KALA BIO, will present a corporate overview at the TD Cowen 44th Annual Healthcare Conference being held in Boston on Monday, March 4, 2024 at 12:50 p.m. ET. Management will also be available for one-on-one meetings on Monday, March 4, 2024.
马萨诸塞州阿灵顿，2024年2月26日（GLOBE NEWSWIRE）——致力于罕见和严重眼部疾病创新疗法研究、开发和商业化的临床阶段生物制药公司KALA BIO, Inc.（纳斯达克股票代码：KALA）今天宣布，KALA BIO董事长兼首席执行官马克·伊维基将在道明考恩第44届年度医疗保健大会上介绍公司概况会议将于美国东部时间2024年3月4日星期一下午12点50分在波士顿举行。管理层还将在2024年3月4日星期一参加一对一的会议。
To access the webcast and subsequent archived recording of the presentation, please visit the "Presentations" section of the KALA website at www.kalarx.com.
要访问演示文稿的网络直播和随后的存档录像，请访问 KALA 网站的 “演示” 部分，网址为 www.kalarx.com。
About KALA BIO, Inc.
关于 KALA BIO, Inc.
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA's biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.
KALA是一家临床阶段的生物制药公司，致力于罕见和严重眼部疾病的创新疗法的研究、开发和商业化。KALA 基于生物制剂的研究疗法利用其专有的间充质干细胞分泌组 (MSC-S) 平台。KALA 的主要候选产品 KPI-012 是人类 MSC-S，它含有许多人类衍生的生物因子，例如生长因子、蛋白酶抑制剂、基质蛋白和神经营养因子，有可能纠正角膜愈合受损，而角膜愈合受损是多种严重眼部疾病的潜在病因。KPI-012 目前正在临床开发中，用于治疗持续性角膜上皮缺损 (PCED)，这是一种罕见的角膜愈合受损疾病，已获得美国食品药品监督管理局的孤儿药和快速通道认定。KALA 还着眼于 KPI-012 的潜在开发，用于治疗边缘干细胞缺乏症和其他威胁视力的罕见角膜疾病，并已启动临床前研究，以评估其 MSC-S 平台对视网膜退行性疾病（例如色素性视网膜炎和斯塔加特病）的潜在效用。有关 KALA 的更多信息，请访问 www.kalarx.com。
Investor Contact:
投资者联系人：
Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200
汉娜·德雷西维奇
hannah.deresiewicz@sternir.com
212-362-1200
译文内容由第三方软件翻译。